For the quarter ending 2025-09-30, GOSS had -$17,376K decrease in cash & cash equivalents over the period. -$36,167K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -48,221 | -74,911 |
| Depreciation and amortization expense | 6 | 12 |
| Stock-based compensation expense | 2,666 | 4,991 |
| In process research and development expenses | 7,476 | - |
| Amortization of operating lease right-of-use assets | 214 | 543 |
| Amortization of long-term debt discount and issuance costs | 248 | 486 |
| Amortization of premium on marketable securities, net of accretion of discounts | 1,585 | 4,611 |
| Loss on disposal of property and equipment | 0 | 0 |
| Receivable from contracts with collaborators | 1,664 | 2,241 |
| Prepaid expenses and other current assets | -879 | 5,369 |
| Other assets | 24 | 100 |
| Operating lease liabilities | 205 | 534 |
| Accounts payable | -795 | -6,774 |
| Accrued expenses and other current liabilities | 1,308 | 363 |
| Accrued research and development expenses | 2,135 | 5,146 |
| Accrued compensation and benefits | 2,809 | -2,834 |
| Contract liabilities | -3,914 | -952 |
| Accrued interest expense | 2,500 | 0 |
| Net cash provided by (used in) operating activities | -36,167 | -86,785 |
| Purchase of marketable securities | 29,586 | 176,533 |
| Maturities of marketable securities | 46,600 | 242,800 |
| Purchase of property and equipment | 0 | 79 |
| Net cash provided by (used in) investing activities | 17,014 | 66,188 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 469 | 372 |
| Proceeds from the exercise of stock options | 465 | 226 |
| Proceeds from the exercise of warrants | 938 | - |
| Proceeds from grant of equity option pursuant to chiesi collaboration agreement | 0 | 0 |
| Principal repayments of long-term debt | 0 | 0 |
| Net cash provided by (used in) financing activities | 1,872 | 598 |
| Effect of exchange rate changes on cash and cash equivalents | -95 | 234 |
| Net decrease in cash and cash equivalents | -17,376 | -19,765 |
| Cash and cash equivalents at beginning of period | 46,074 | - |
| Cash and cash equivalents at end of period | 8,933 | - |
Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)